aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАНateroskleroz-588Research ArticleОБЗОРЫREVIEWSСвободно-радикальное окисление и атеросклерозFree-radical oxidation and atherosclerosisВоробьеваЕ. Н.VorobiovaE. N.

ОУ ВПО Алтайский государственный медицинский университет

НИИ терапии

Алтайская лаборатория эпидемиологии, прогнозирования и профилактики неинфекционных заболеваний

Барнаул

SB RAMS

Altai State Medical University

Research Institute of Therapy

Altai Laboratory of Epidemiology, Forecasting and Prevention of Non-Communicable Diseases Noncommunicable diseases

Barnaul

elenavorobyova@yandex.ruСимоноваГ. И.SimonovaG. I.

ОУ ВПО Алтайский государственный медицинский университет

НИИ терапии

Алтайская лаборатория эпидемиологии, прогнозирования и профилактики неинфекционных заболеваний

Барнаул

SB RAMS

Altai State Medical University

Research Institute of Therapy

Altai Laboratory of Epidemiology, Forecasting and Prevention of Non-Communicable Diseases Noncommunicable diseases

Barnaul

ВоробьевР. И.VorobiovR. I.

ОУ ВПО Алтайский государственный медицинский университет

НИИ терапии

Алтайская лаборатория эпидемиологии, прогнозирования и профилактики неинфекционных заболеваний

Барнаул

SB RAMS

Altai State Medical University

Research Institute of Therapy

Altai Laboratory of Epidemiology, Forecasting and Prevention of Non-Communicable Diseases Noncommunicable diseases

Barnaul

ЛещенкоИ. Ж.LeschenkoI. G.

ОУ ВПО Алтайский государственный медицинский университет

НИИ терапии

Алтайская лаборатория эпидемиологии, прогнозирования и профилактики неинфекционных заболеваний

Барнаул

SB RAMS

Altai State Medical University

Research Institute of Therapy

Altai Laboratory of Epidemiology, Forecasting and Prevention of Non-Communicable Diseases Noncommunicable diseases

Barnaul

Росздрав; РАМНРоссияRoszdrav; RAMSRussian Federation201027032022622027Copyright © Воробьева Е.Н., Симонова Г.И., Воробьев Р.И., Лещенко И.Ж., 20222022Воробьева Е.Н., Симонова Г.И., Воробьев Р.И., Лещенко И.Ж.Vorobiova E.N., Simonova G.I., Vorobiov R.I., Leschenko I.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/588

   Описана важная биологическая роль реактивных активных форм кислорода, которые конститутивно генерируются в различных клетках здоровых организмов, от одноклеточных до высокоорганизованных, выполняя, благодаря высочайшей химической реактивности и весьма короткой продолжительности жизни, жизненно важную функцию сигнальных внутриклеточных трансдукторов и межклеточных медиаторов для реализации срочной и отсроченной адаптивной перестройки метаболизма в тканях, в том числе в системе кровообращения. Показано, что при значительном накоплении в организме таких молекул их медиаторная функция трансформируется в повреждающую, обусловленную окислением и разрушением тканевых липидов, белков и нуклеиновых кислот с развитием патологических повреждений органов и тканей. Эта концепция согласуется с многочисленными клиническими сведениями, что у больных эссенциальной гипертонией, атеросклерозом, ишемической болезнью сердца и инфарктом миокарда тканевой и плазменный уровень активных форм кислорода и продуктов окислительного повреждения клеточных биополимеров во много раз выше величин, наблюдаемых у здоровых людей даже в период экстремальных ситуаций, причем патогенетически значимыми в данном случае выступают локальная и / или системная гиперпродукция супероксидного и гидроксильного радикалов, гидропероксида, оксида азота, пероксинитрита и других активных форм кислорода.

   The important biological role reactive oxyradicals is described which are generated in various cells of able-bodied organisms, from unicellular up to highorganized, carrying out, due to a highest chemical reactivity and rather short lifetime, vital function alarm endocellular messengers and intercellular mediators for realization of the expedited and deferred adaptable rearrangement of a metabolism in tissues, including in system of a circulation. At the same time at appreciable accumulation in an organism of such moleculas them mediator function is transformed in damaging, caused byoxidation and destruction of histic lipids, proteins and nucleic acids with development of pathological damages of members and tissues. This concept is compounded with the numerous clinical items of information, that at the patients by an essential hypertension, atherosclerosis, ischemic illness of heart and myocardial infarction histic and the plasma level reactive oxyradicals and products oxidative damage cell’s biopolimers is many times higher than sizes observable at the able-bodied people even in the term of extreme situations, and pathological important in this case acts local and – or systemic hyperproduction of superoxidic and hydroxyl radicals, peroxinitrit, oxide of nitrogen, and other awake forms of oxygen.

cердечно-сосудистые заболеванияфакторы рискасвободнорадикальное окислениедислипопротеинемииcardiovascular diseasesrisk factorsfree-radical oxidationdyslipoproteinemiasReferencesЩепин О. П. Основные тенденции формирования здоровья населения Российской Федерации в 1998 г. / О. П. Щепин, В. К. Овчаров, Е. П. Какорина // Пробл. социальной гигиены, здравоохранения и истории медицины. – 1999. – № 6. – С. 3–11.Щепин О. П. Основные тенденции формирования здоровья населения Российской Федерации в 1998 г. / О. П. Щепин, В. К. Овчаров, Е. П. Какорина // Пробл. социальной гигиены, здравоохранения и истории медицины. – 1999. – № 6. – С. 3–11.Чазов Е. И. Проблемы лечения больных ишемической болезнью сердца / Е. И. Чазов // Терапевт. арх. – 2000. – № 9. – С. 5–9.Чазов Е. И. Проблемы лечения больных ишемической болезнью сердца / Е. И. Чазов // Терапевт. арх. – 2000. – № 9. – С. 5–9.Ross R. The Pathogenesis of Atherosclerosis: An Update // Atherosclerosis Beyond Cholesterd. Hanover, 1992. 17 p.Ross R. The Pathogenesis of Atherosclerosis: An Update // Atherosclerosis Beyond Cholesterd. Hanover, 1992. 17 p.Stamler J. Established major coronary risk factors // In Coronary heart disease epidemiology / Eds. M. Marmot, P. Elliott. Oxford: Oxford University Press, 1996. P. 35–62.Stamler J. Established major coronary risk factors // In Coronary heart disease epidemiology / Eds. M. Marmot, P. Elliott. Oxford: Oxford University Press, 1996. P. 35–62.Gianturco S. H., Bradley W. A. Atherosclerosis: cell biology and lipoproteins // Current Opinion in Lipidology. 1994. Vol. 5. Р. 313–315.Gianturco S. H., Bradley W. A. Atherosclerosis: cell biology and lipoproteins // Current Opinion in Lipidology. 1994. Vol. 5. Р. 313–315.a) Parthasarathy S., Santanam N. Potential Role of Oxidized Lipids and Lipoproteins in Antioxidant Defense // Free Rad. Res. 2000. Vol. 33. Р. 197–215; b) Parthasarathy S., Santanam N., Ramachandran S., Meilhac O. Oxidants and antioxidants in athero genesis: an appraisal // J. Lipid Res. 1999. Vol. 40. P. 2143–2157.a) Parthasarathy S., Santanam N. Potential Role of Oxidized Lipids and Lipoproteins in Antioxidant Defense // Free Rad. Res. 2000. Vol. 33. Р. 197–215; b) Parthasarathy S., Santanam N., Ramachandran S., Meilhac O. Oxidants and antioxidants in athero genesis: an appraisal // J. Lipid Res. 1999. Vol. 40. P. 2143–2157.Finkel T. Oxygen radicals and signaling // Current Opinion in Cell Biology. 1998. Vol. 10. P. 248–253.Finkel T. Oxygen radicals and signaling // Current Opinion in Cell Biology. 1998. Vol. 10. P. 248–253.Halliwell B. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans // Free Radic. Res. 1996. Vol. 25. Р. 57–74.Halliwell B. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans // Free Radic. Res. 1996. Vol. 25. Р. 57–74.Harrison D. G. Endothelial function and oxidant stress // Clin. Cardiol. 1997. Vol. 20. Suppl. II: II-11-II-17.Harrison D. G. Endothelial function and oxidant stress // Clin. Cardiol. 1997. Vol. 20. Suppl. II: II-11-II-17.Howarth P. H. Pathogenic mechanisms: a rational basis for treatment // BMJ. 1998. Vol. 316. P. 758–761.Howarth P. H. Pathogenic mechanisms: a rational basis for treatment // BMJ. 1998. Vol. 316. P. 758–761.Luscher T. F., Noll G., Vanhoutte P. M. Endothelial dysfunction in hypertension // J. Hypertens. 1996. Vol. 14 (5). Р. 383–393.Luscher T. F., Noll G., Vanhoutte P. M. Endothelial dysfunction in hypertension // J. Hypertens. 1996. Vol. 14 (5). Р. 383–393.Daugherty M. O., Rich G. F., Johns R. A. Vascular endothelium // Current Opinion in Anaesthesiology. 1995. N 8. P. 88–94.Daugherty M. O., Rich G. F., Johns R. A. Vascular endothelium // Current Opinion in Anaesthesiology. 1995. N 8. P. 88–94.Griendling K. K., Minieri C. A., Ollerenshaw J. D., Alexander R. W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells // Circulation Res. 1994. Vol. 74. P. 1141–1148.Griendling K. K., Minieri C. A., Ollerenshaw J. D., Alexander R. W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells // Circulation Res. 1994. Vol. 74. P. 1141–1148.Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease // J. Pathol. 2000. Vol. 190. P. 244–254, 319–326.Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease // J. Pathol. 2000. Vol. 190. P. 244–254, 319–326.Cooke J. P., Dzau V. J. Nitric oxide synthase: Role in the Genesis of Vascular Disease // Ann. Rev. Med. 1997. Vol. 48. P. 489–509.Cooke J. P., Dzau V. J. Nitric oxide synthase: Role in the Genesis of Vascular Disease // Ann. Rev. Med. 1997. Vol. 48. P. 489–509.Ortenblad N., Madsen K., Djurhuus M. S. Antioxidant status and lipid peroxidation after short-term maximal exercise in trained and untrained humans // Am. J. Physiol. 1997. Vol. 272 (4). Р. 1258–1263.Ortenblad N., Madsen K., Djurhuus M. S. Antioxidant status and lipid peroxidation after short-term maximal exercise in trained and untrained humans // Am. J. Physiol. 1997. Vol. 272 (4). Р. 1258–1263.Lavreni A., Salobir B. G., Keber I. et al. Physical Training Improves Flow-Mediated Dilation in Patients With the Polymetabolic Syndrome // Arteriosclerosis, Thrombosis, and Vascular Biology. 2000. Vol. 20. P. 551–559.Lavreni A., Salobir B. G., Keber I. et al. Physical Training Improves Flow-Mediated Dilation in Patients With the Polymetabolic Syndrome // Arteriosclerosis, Thrombosis, and Vascular Biology. 2000. Vol. 20. P. 551–559.Steinberg D. Low Density Lipoprotein Oxidation and Its Pathobiological Significance // J. Biol. Chem. 1997. Vol. 272, N 34. Р. 20963–20966.Steinberg D. Low Density Lipoprotein Oxidation and Its Pathobiological Significance // J. Biol. Chem. 1997. Vol. 272, N 34. Р. 20963–20966.Capaldo B., Guardasole V., Pardo F. et al. Abnormal Vascular Reactivity in Growth Hormone Deficiency // Circulation. 2001. Vol. 103. Р. 520–524.Capaldo B., Guardasole V., Pardo F. et al. Abnormal Vascular Reactivity in Growth Hormone Deficiency // Circulation. 2001. Vol. 103. Р. 520–524.Ouchi N., Kihara S., Arita Y. et al. Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages // Ibid. Р. 1057–1063.Ouchi N., Kihara S., Arita Y. et al. Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages // Ibid. Р. 1057–1063.Bredt D. S. Endogenous nitric oxide synthesis: biological functions and pathophysiology // Free Rad. Res. 1999. Vol. 31. P. 577–581.Bredt D. S. Endogenous nitric oxide synthesis: biological functions and pathophysiology // Free Rad. Res. 1999. Vol. 31. P. 577–581.Beckman J. S., Carson M., Smith C. D., Koppenol W. H. SLS, SOD and peroxynitrite // Nature. 1993. Vol. 364. P. 584–587.Beckman J. S., Carson M., Smith C. D., Koppenol W. H. SLS, SOD and peroxynitrite // Nature. 1993. Vol. 364. P. 584–587.Nathan C. F. Secretory products of macrophages // J. Clin. Invest. 1987. Vol. 79.Nathan C. F. Secretory products of macrophages // J. Clin. Invest. 1987. Vol. 79.Givertz M. M., Colucci W. S. New targets for heart-failure therapy: endothelin, in-flammatory cytokines, and oxidative stress // Lancet. 1998. Vol. 352 (1). P. 34–38.Givertz M. M., Colucci W. S. New targets for heart-failure therapy: endothelin, in-flammatory cytokines, and oxidative stress // Lancet. 1998. Vol. 352 (1). P. 34–38.Nathan C. F., Ortenblad N., Madsen K., Djurhu us M. S. Antioxidant status and lipid peroxidation after short-term maximal exercise in trained and untrained humans // Am. J. Physiol. 1997. Vol. 272 (4). Р. 1258–1263.Nathan C. F., Ortenblad N., Madsen K., Djurhu us M. S. Antioxidant status and lipid peroxidation after short-term maximal exercise in trained and untrained humans // Am. J. Physiol. 1997. Vol. 272 (4). Р. 1258–1263.Hwang S. J., Ballantyne C. M., Sharrett A. R. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases (ARIC) // Circulation. 1997. Vol. 96. Р. 4219–4225.Hwang S. J., Ballantyne C. M., Sharrett A. R. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases (ARIC) // Circulation. 1997. Vol. 96. Р. 4219–4225.Spiecker M., Peng H. B., Liao J. K. Inhibition of endothelial vascular cell adhesion molecule-1 expression bynitric oxide involves the induction and nuclear translocation of NfkB // J. Biol. Chem. 1997. Vol. 272. P. 30969–30974.Spiecker M., Peng H. B., Liao J. K. Inhibition of endothelial vascular cell adhesion molecule-1 expression bynitric oxide involves the induction and nuclear translocation of NfkB // J. Biol. Chem. 1997. Vol. 272. P. 30969–30974.Stangl H., Hyatt M., Hobbs H. Transport of Lipids from High and Low Density Lipoproteins via Scavenger Receptor-BI // J. Biol. Chem. 1999. Vol. 274, Issue 46. P. 32692–32698.Stangl H., Hyatt M., Hobbs H. Transport of Lipids from High and Low Density Lipoproteins via Scavenger Receptor-BI // J. Biol. Chem. 1999. Vol. 274, Issue 46. P. 32692–32698.Blumenthal J. A., O’Connor C., Hinderliter A. et al. Psychosocial factors and coronary disease. A national multicenter clinical trial (ENRICHD) with a North Carolina focus // N. C. Med. J. 1997. Vol. 58. Р. 440–444.Blumenthal J. A., O’Connor C., Hinderliter A. et al. Psychosocial factors and coronary disease. A national multicenter clinical trial (ENRICHD) with a North Carolina focus // N. C. Med. J. 1997. Vol. 58. Р. 440–444.Laursen J. B., Rajagopalan S., Galis Z. et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension // Circulation. 1997. Vol. 95. P. 588–593.Laursen J. B., Rajagopalan S., Galis Z. et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension // Circulation. 1997. Vol. 95. P. 588–593.Yokode M., Ueyama K., Arai N. H. et al. Modification of high- and low-density lipoproteins by cigarette smoke oxidants // Ann. N.Y. Acad. Sci. 1996. Vol. 786. Р. 245–251.Yokode M., Ueyama K., Arai N. H. et al. Modification of high- and low-density lipoproteins by cigarette smoke oxidants // Ann. N.Y. Acad. Sci. 1996. Vol. 786. Р. 245–251.Zafari A. M., Ushio-Fukai M., Akers M. et al. Role of NADH / NADPH oxidase-derived H<sub>2</sub>O<sub>2</sub> in angioten-sin II-induced vascular hypertrophy // Hypertension. 1998. Vol. 32 (30). P. 488–495.Zafari A. M., Ushio-Fukai M., Akers M. et al. Role of NADH / NADPH oxidase-derived H<sub>2</sub>O<sub>2</sub> in angioten-sin II-induced vascular hypertrophy // Hypertension. 1998. Vol. 32 (30). P. 488–495.Shephard G., Cobbe S. M., Ford J. еt al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group (WOSCOPS) // N. Engl. J. Med. 1995. Vol. 333. P. 1301–1307.Shephard G., Cobbe S. M., Ford J. еt al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group (WOSCOPS) // N. Engl. J. Med. 1995. Vol. 333. P. 1301–1307.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. 1994. Vol. 344. Р. 1383–1389.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) // Lancet. 1994. Vol. 344. Р. 1383–1389.Vincent H. K., Powers S. K., Stewart D. J. et al. Obesity is associated with in-creased myocardial oxidative stress. Dept. of Exercise Sport Sci., Center Exercise Sci., Univ. of Florida, Gainesville, USA // Int. J. Obes. Relat. Metab. Disord. 1999. Vol. 23. P. 67–74.Vincent H. K., Powers S. K., Stewart D. J. et al. Obesity is associated with in-creased myocardial oxidative stress. Dept. of Exercise Sport Sci., Center Exercise Sci., Univ. of Florida, Gainesville, USA // Int. J. Obes. Relat. Metab. Disord. 1999. Vol. 23. P. 67–74.Sen-Banerjee S., Siles X., Campos H. Tobacco Smoking Modifies Association Between Gln-Arg192 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction // Arteriosclerosis, Thrombosis, and Vascular Biology. 2000. Vol. 20. Р. 2120–2128.Sen-Banerjee S., Siles X., Campos H. Tobacco Smoking Modifies Association Between Gln-Arg192 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction // Arteriosclerosis, Thrombosis, and Vascular Biology. 2000. Vol. 20. Р. 2120–2128.Kasim-Karakas S. E. Impact of n-3 fatty acids on lipoprotein metabolism // Current Opinion in Lipidology. 1995. Vol. 6. Р. 167–171.Kasim-Karakas S. E. Impact of n-3 fatty acids on lipoprotein metabolism // Current Opinion in Lipidology. 1995. Vol. 6. Р. 167–171.Sanchez-Quesada J. L., Homs-Serradesanferm R., Serrat-Serrat J. et al. Increase of LDL suscepti bility to oxidation occurring after intense, long duration aerobic exercise // Atherosclerosis. 1995. Vol. 118. Р. 297-305.Sanchez-Quesada J. L., Homs-Serradesanferm R., Serrat-Serrat J. et al. Increase of LDL suscepti bility to oxidation occurring after intense, long duration aerobic exercise // Atherosclerosis. 1995. Vol. 118. Р. 297-305.

The authors declare that there are no conflicts of interest present.